Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) EBITDA (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed EBITDA for 4 consecutive years, with -$12.7 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 80.2% to -$12.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$126.8 million, a 28.46% increase, with the full-year FY2011 number at -$114.1 million, down 19.2% from a year prior.
  • EBITDA was -$12.7 million for Q3 2025 at Lexicon Pharmaceuticals, down from $3.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $3.7 million in Q2 2025 to a low of -$64.3 million in Q3 2024.